CRL

Charles River Laboratories International, Inc. (CRL) | Rumor.io

Charles River Laboratories International

CRL

Attention (50-day avg)0%

Attention rank (50-day avg)#1,703

Bullish sentiment (50-day avg)100%

Price to earnings ratio681.3

Market capitalization14.2B

Earnings per share-4.8

Dividend yield (TTM)0.41%

Revenue (annual)4B

Net income (annual)-142.2M

Social

What share of all stock conversation is about CRL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Sep 11

The stock has a PDUFA date for an FDA decision next Saturday, September 19th, which may lead to an announcement as early as the Friday before.
Charles River Laboratories International, Inc. received a CRL last year due to issues with a manufacturing plant, but has since resubmitted the BLA and is now on the FDA's calendar for review.
The company has an 18% short interest, which could be a significant factor in the stock's performance.

Generated by AI

Sentiment

Of the messages about CRL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	77.8% +1.17
Bearish	—	—	—	22.2% -1.17

Bullish· Jul 23

$CRL is expected to beat expectations.
Charles River Laboratories International, Inc. is seen as a strong performer.
Investors are optimistic about CRL's prospects.

Bearish· Nov 9

Charles River Laboratories International, Inc. ($CRL) is seeing more selling pressure than buying pressure.
The current market environment is unfavorable for $CRL, contributing to its decline.
Investors are losing confidence in $CRL, leading to increased selling activity.

Generated by AI

Topics

Of the messages about CRL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	50%	66.67%	52.63%	8.22%
Announcements	0%	0%	42.11%	12.15%
Analysts	50%	33.33%	5.26%	40.05%
Earnings	0%	0%	0%	1.83%
Controversies	0%	0%	0%	0.31%
Macro	0%	0%	0%	37.43%

Earnings· Aug 8

Charles River Laboratories International, Inc. (CRL) reported earnings of $1.62 per share, beating the consensus estimate of $1.46.
CRL's revenue for the quarter was $585.30 million, also beating estimates.
The company beat expectations by $0.16 per share, with an earnings per share (EPS) beat of 11 cents on the Estimize consensus.

Analysts· Feb 17

Charles River Laboratories International ($CRL) has had its price target lowered by several analysts, with Bank of America cutting its target to $400, KeyCorp to $390, Wells Fargo to $390, Morgan Stanley to $430, and UBS to $420.
Analysts have maintained a generally positive outlook on the company, with Citigroup upgrading its rating to Buy and setting a $400 price target, and Morgan Stanley maintaining an Overweight rating with a lowered price target of $430.
The price target updates were published on February 17, 2022, with some analysts citing a potential upside of 27.53% to 35.11% based on the new targets.

Announcements· Jul 24

Charles River Laboratories International, Inc. ($CRL) saw a 7.4% stock price increase due to strong demand for biotech testing services.
The company specializes in drug discovery and safety testing for biotech and pharmaceutical clients.
The stock's positive movement was driven by the growing need for laboratory research services in the biotech industry.

Macro· May 24

Charles River Laboratories International, Inc. (CRL) may see short-term earnings impacted by inflation, which takes time to pass on to consumers.
The company's UK small cap stocks are considered undervalued, with a 75% decline.
Inflation is a key concern for CRL's short-term earnings.

Generated by AI

Community

Of the messages about CRL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	68.29%	20.4%	9.38%
Newcomers	100%	31.71%	79.6%	90.62%

Regulars· May 11

Charles River Laboratories has reported first-quarter 2023 results, beating expectations on both earnings and revenue.
The company's non-GAAP EPS of $2.78 exceeded the consensus estimate of $2.59, and revenue of $1.03B exceeded the consensus estimate by $43.94M.
Charles River Laboratories has raised the low end of its FY23 guidance after the strong Q1 results.

Newcomers· Sep 11

The Charles River Laboratories International, Inc. (CRL) stock is expected to have a significant catalyst next Friday, with a PDUFA date for an FDA decision scheduled for September 19th.
The company received a CRL (complete response letter) last year due to manufacturing plant issues, but has since resubmitted the BLA (biologics license application) and is awaiting the FDA's decision.
With 18% short interest, there is a possibility that the stock could be heavily influenced by the upcoming FDA decision, making it a potentially volatile and attention-grabbing asset.

Generated by AI

Cooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]

19h agoYahoo Finance

Jefferies raises Charles River Labs stock price target on cost efficiency outlook

2d agoInvesting.com

Also Discussed

Investors talking about CRL also mention

#	Name	Attention
1	ICON plcICLR	0%0
2	Inotiv Inc.NOTV	0%0
3	Medpace Holdings, Inc.MEDP	0%+0
4	Installed Building Products, Inc.IBP	0%0
5	Lyell Immunopharma, Inc.LYEL	0.01%new
6	iShares Core Aggressive Allocation ETFAOA	0%0
7	ProShares Ultra Health Care ETFRXL	0.01%+0
8	Dream Finders Homes Inc Class A Common StockDFH	0%+0
9	Polaris Inc.PII	0%0
10	Waste Connections, Inc.WCN	0%new

Charles River Laboratories International, Inc.

Healthcare
Diagnostics & Research

Charles River Laboratories International, Inc. is a global drug development services company that supports pharmaceutical, biotechnology, and medical device organizations across the research and preclinical stages. Charles River Laboratories provides research models, discovery services, non-clinical safety assessment, and manufacturing-related testing solutions that help clients evaluate new therapies and products before clinical use. Its business spans three main segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. The company also offers specialized support for biologics, microbial testing, endotoxin testing, and cell-based research, serving customers in life sciences, academia, and government research. Headquartered in Wilmington, Massachusetts, Charles River Laboratories plays a key role in the outsourced research and development ecosystem by supplying the tools, services, and scientific expertise used to advance drug discovery and product safety worldwide.

Website

Location

251 Ballardvale Street

Wilmington, MA, 01887

United States

Social

What share of all stock conversation is about CRL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Sep 11

The stock has a PDUFA date for an FDA decision next Saturday, September 19th, which may lead to an announcement as early as the Friday before.
Charles River Laboratories International, Inc. received a CRL last year due to issues with a manufacturing plant, but has since resubmitted the BLA and is now on the FDA's calendar for review.
The company has an 18% short interest, which could be a significant factor in the stock's performance.

Generated by AI

Sentiment

Of the messages about CRL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	77.8% +1.17
Bearish	—	—	—	22.2% -1.17

Bullish· Jul 23

$CRL is expected to beat expectations.
Charles River Laboratories International, Inc. is seen as a strong performer.
Investors are optimistic about CRL's prospects.

Bearish· Nov 9

Charles River Laboratories International, Inc. ($CRL) is seeing more selling pressure than buying pressure.
The current market environment is unfavorable for $CRL, contributing to its decline.
Investors are losing confidence in $CRL, leading to increased selling activity.

Generated by AI

Topics

Of the messages about CRL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	50%	66.67%	52.63%	8.22%
Announcements	0%	0%	42.11%	12.15%
Analysts	50%	33.33%	5.26%	40.05%
Earnings	0%	0%	0%	1.83%
Controversies	0%	0%	0%	0.31%
Macro	0%	0%	0%	37.43%

Earnings· Aug 8

Charles River Laboratories International, Inc. (CRL) reported earnings of $1.62 per share, beating the consensus estimate of $1.46.
CRL's revenue for the quarter was $585.30 million, also beating estimates.
The company beat expectations by $0.16 per share, with an earnings per share (EPS) beat of 11 cents on the Estimize consensus.

Analysts· Feb 17

Charles River Laboratories International ($CRL) has had its price target lowered by several analysts, with Bank of America cutting its target to $400, KeyCorp to $390, Wells Fargo to $390, Morgan Stanley to $430, and UBS to $420.
Analysts have maintained a generally positive outlook on the company, with Citigroup upgrading its rating to Buy and setting a $400 price target, and Morgan Stanley maintaining an Overweight rating with a lowered price target of $430.
The price target updates were published on February 17, 2022, with some analysts citing a potential upside of 27.53% to 35.11% based on the new targets.

Announcements· Jul 24

Charles River Laboratories International, Inc. ($CRL) saw a 7.4% stock price increase due to strong demand for biotech testing services.
The company specializes in drug discovery and safety testing for biotech and pharmaceutical clients.
The stock's positive movement was driven by the growing need for laboratory research services in the biotech industry.

Macro· May 24

Charles River Laboratories International, Inc. (CRL) may see short-term earnings impacted by inflation, which takes time to pass on to consumers.
The company's UK small cap stocks are considered undervalued, with a 75% decline.
Inflation is a key concern for CRL's short-term earnings.

Generated by AI

Community

Of the messages about CRL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	68.29%	20.4%	9.38%
Newcomers	100%	31.71%	79.6%	90.62%

Regulars· May 11

Charles River Laboratories has reported first-quarter 2023 results, beating expectations on both earnings and revenue.
The company's non-GAAP EPS of $2.78 exceeded the consensus estimate of $2.59, and revenue of $1.03B exceeded the consensus estimate by $43.94M.
Charles River Laboratories has raised the low end of its FY23 guidance after the strong Q1 results.

Newcomers· Sep 11

The Charles River Laboratories International, Inc. (CRL) stock is expected to have a significant catalyst next Friday, with a PDUFA date for an FDA decision scheduled for September 19th.
The company received a CRL (complete response letter) last year due to manufacturing plant issues, but has since resubmitted the BLA (biologics license application) and is awaiting the FDA's decision.
With 18% short interest, there is a possibility that the stock could be heavily influenced by the upcoming FDA decision, making it a potentially volatile and attention-grabbing asset.

Generated by AI

Charles River Laboratories International

Social

Sep 11

Bullish· Jul 23

Bearish· Nov 9

Earnings· Aug 8

Analysts· Feb 17

Announcements· Jul 24

Macro· May 24

Regulars· May 11

Newcomers· Sep 11

UBS resumes Charles River Labs stock coverage with buy rating

Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery

Jefferies raises Charles River Labs stock price target on cost efficiency outlook

Mizuho raises Charles River Labs stock price target to $295 on outlook

TD Cowen raises Charles River Labs stock price target on growth outlook

Charles River Labs sets 2030 targets, reaffirms 2026 guidance

Also Discussed

Charles River Laboratories International, Inc.

Company Information

Location

UBS resumes Charles River Labs stock coverage with buy rating

Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery

Jefferies raises Charles River Labs stock price target on cost efficiency outlook

Mizuho raises Charles River Labs stock price target to $295 on outlook

TD Cowen raises Charles River Labs stock price target on growth outlook

Charles River Labs sets 2030 targets, reaffirms 2026 guidance

Also Discussed

Social

Sep 11

Bullish· Jul 23

Bearish· Nov 9

Earnings· Aug 8

Analysts· Feb 17

Announcements· Jul 24

Macro· May 24

Regulars· May 11

Newcomers· Sep 11